Your browser is no longer supported. Please, upgrade your browser.
Settings
EXEL Exelixis, Inc. daily Stock Chart
EXEL [NASD]
Exelixis, Inc.
Index- P/E54.99 EPS (ttm)0.49 Insider Own0.90% Shs Outstand288.38M Perf Week-3.59%
Market Cap7.82B Forward P/E37.65 EPS next Y0.72 Insider Trans-25.70% Shs Float278.43M Perf Month2.69%
Income150.90M PEG1.20 EPS next Q0.12 Inst Own82.80% Short Float6.33% Perf Quarter3.32%
Sales410.00M P/S19.07 EPS this Y63.70% Inst Trans3.23% Short Ratio4.90 Perf Half Y36.92%
Book/sh0.81 P/B33.47 EPS next Y46.04% ROA26.10% Target Price32.71 Perf Year60.32%
Cash/sh1.27 P/C21.30 EPS next 5Y46.00% ROE101.20% 52W Range14.22 - 32.50 Perf YTD81.82%
Dividend- P/FCF41.30 EPS past 5Y-19.90% ROI-15.10% 52W High-17.14% Beta1.90
Dividend %- Quick Ratio4.30 Sales past 5Y-7.90% Gross Margin96.90% 52W Low89.38% ATR1.14
Employees287 Current Ratio4.30 Sales Q/Q145.20% Oper. Margin39.30% RSI (14)53.88 Volatility4.41% 3.96%
OptionableYes Debt/Eq0.00 EPS Q/Q690.80% Profit Margin36.80% Rel Volume0.53 Prev Close27.11
ShortableYes LT Debt/Eq0.00 EarningsNov 01 AMC Payout0.00% Avg Volume3.60M Price26.93
Recom2.30 SMA202.23% SMA502.98% SMA20011.36% Volume194,800 Change-0.66%
Oct-17-17Reiterated RBC Capital Mkts Outperform $33 → $39
Oct-17-17Reiterated Needham Buy $30 → $33
Oct-16-17Reiterated SunTrust Buy $32 → $35
Sep-22-17Downgrade Leerink Partners Outperform → Mkt Perform
Sep-15-17Initiated RBC Capital Mkts Outperform $32
Sep-12-17Reiterated Needham Buy $28 → $30
Jul-14-17Initiated SunTrust Buy $33
Mar-31-17Initiated Needham Buy $28
Mar-16-17Initiated Oppenheimer Perform
Feb-28-17Downgrade Stifel Buy → Hold $21 → $22
Nov-03-16Initiated Deutsche Bank Buy $17
Oct-10-16Upgrade Piper Jaffray Neutral → Overweight
Sep-15-16Reiterated Stifel Buy $12 → $15
Aug-04-16Reiterated Stifel Buy $10 → $12
Jun-21-16Reiterated Leerink Partners Outperform $8 → $10
Apr-26-16Reiterated Stifel Buy $7 → $8
Apr-04-16Upgrade Stifel Hold → Buy $7
Jan-19-16Upgrade Leerink Partners Mkt Perform → Outperform
Sep-02-14Downgrade Stifel Buy → Hold
Feb-07-14Reiterated Stifel Buy $9 → $11
Dec-08-17 08:04AM  See what the IHS Markit Score report has to say about Exelixis Inc. Markit
Dec-07-17 09:11AM  Is Exelixis, Inc. a Buy? Motley Fool
Dec-06-17 04:50PM  Top 5 Biotech Stocks for 2017 Investopedia
Dec-04-17 01:45PM  Analysts Recommendations for Regeneron Market Realist
Dec-01-17 03:00AM  Stocks To Watch: Exelixis Sees Relative Strength Rating Rise To 84 Investor's Business Daily
Nov-30-17 08:02AM  See what the IHS Markit Score report has to say about Exelixis Inc. Markit
Nov-27-17 08:15AM  Report: Developing Opportunities within PayPal, Exelixis, International Business Machines, Opko Health, Envision Healthcare, and Zynga Future Expectations, Projections Moving into 2018 GlobeNewswire
08:02AM  See what the IHS Markit Score report has to say about Exelixis Inc. Markit
07:50AM  Blog Exposure - Exelixis Announces Phase-3 CELESTIAL Trial Results of Cabozantinib in Previously Treated Advanced Hepatocellular Carcinoma ACCESSWIRE
Nov-25-17 11:02AM  Best Growth Stocks To Buy Simply Wall St.
Nov-23-17 07:31AM  Gauging Exelixiss High Hopes for Cotellic Market Realist
Nov-22-17 10:32AM  Inside Exelixiss Label Expansion Collaborations for Cabozantinib Market Realist
09:03AM  What Else Could Boost Exelixiss Future Revenues? Market Realist
07:33AM  Behind Exelixiss Cabometyx Strategy for 2018 Market Realist
Nov-21-17 04:45PM  Exelixis Announces Webcasts of Upcoming November Investor Conference Presentations Business Wire
04:30PM  Exelixis Announces Phase 3 CELESTIAL Trial Results of Cabozantinib in Previously Treated Advanced Hepatocellular Carcinoma to be Presented at 2018 Gastrointestinal Cancers Symposium Business Wire
02:55PM  Reading the Expectations for Exelixiss Net Profit Margin in 2017 Market Realist
01:25PM  Whats Really Driving Exelixiss 2017 Revenues? Market Realist
11:54AM  Exelixis and Peers in November: Analyst Recommendations Market Realist
08:02AM  See what the IHS Markit Score report has to say about Exelixis Inc. Markit
08:00AM  Exelixis, Inc. breached its 50 day moving average in a Bearish Manner : EXEL-US : November 21, 2017 Capital Cube
Nov-20-17 12:23PM  ETFs with exposure to Exelixis, Inc. : November 20, 2017 Capital Cube
08:02AM  See what the IHS Markit Score report has to say about Exelixis Inc. Markit
Nov-17-17 08:02AM  See what the IHS Markit Score report has to say about Exelixis Inc. Markit
Nov-16-17 09:41AM  See what the IHS Markit Score report has to say about Exelixis Inc. Markit
Nov-15-17 08:03AM  See what the IHS Markit Score report has to say about Exelixis Inc. Markit
Nov-12-17 09:09AM  Better Buy: Exelixis, Inc. vs. Novartis AG Motley Fool
Nov-10-17 08:08AM  See what the IHS Markit Score report has to say about Exelixis Inc. Markit
07:59AM  Exelixis, Inc. breached its 50 day moving average in a Bearish Manner : EXEL-US : November 10, 2017 Capital Cube
Nov-09-17 12:40PM  ETFs with exposure to Exelixis, Inc. : November 9, 2017 Capital Cube
12:39PM  Perrigo (PRGO) Q3 Earnings Top, 2017 View Raised, Shares Up Zacks
09:45AM  Merrimack (MACK) Q3 Loss Narrower than Expected, Stock Up Zacks
09:30AM  Catalyst (CPRX) Posts Narrower-Than-Expected Loss in Q3 Zacks
09:09AM  VIVUS (VVUS) Q3 Loss Narrows, Qsymia Falters, Shares Down Zacks
07:55AM  Aerie (AERI) Q3 Loss Wider Than Expected, Pipeline in Focus Zacks
Nov-08-17 12:21PM  Jazz Pharmaceuticals (JAZZ) Q3 Earnings Top, 2017 View Cut Zacks
12:16PM  Regeneron (REGN) Beats on Q3 Earnings & Sales, Shares Up Zacks
11:56AM  Agenus (AGEN) Reports In Line Loss in Q3, Revenues Lag Zacks
10:12AM  Infinity (INFI) Q3 Loss Narrower than Expected, View Intact Zacks
10:07AM  AVEO Pharmaceuticals Q3 Loss Narrows, Focus on Fotivda Zacks
09:53AM  Arena Pharmaceuticals (ARNA) Q3 Loss Widens Y/Y, Sales Beat Zacks
Nov-07-17 04:05PM  Exelixis to Present at the Stifel 2017 Healthcare Conference on November 14th Business Wire
Nov-06-17 04:46PM  Edited Transcript of EXEL earnings conference call or presentation 1-Nov-17 9:00pm GMT Thomson Reuters StreetEvents
03:25PM  Top 5 Biotech Stocks for 2017 Investopedia
02:56PM  Exelixis, Inc. Looks Ahead -- but the 3rd Quarter Wasn't Too Shabby Motley Fool
Nov-03-17 03:22PM  Spectrum (SPPI) Earnings, Sales Beat Q3 Estimates Zacks
01:08PM  Achillion (ACHN) Q3 Loss Narrows, Pipeline Expansion in Focus Zacks
10:07AM  Exelixis, Inc. :EXEL-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017 Capital Cube
09:23AM  3 Reasons Behind Exelixis Stock's Big Bounce Motley Fool
09:21AM  Radius Health (RDUS) Earnings Miss in Q3, Tymlos in Focus Zacks
08:00AM  Today's Research Reports on Stocks to Watch: Exelixis, Inc. and Agios Pharmaceuticals ACCESSWIRE
03:00AM  Exelixis Scores Relative Strength Rating Upgrade Investor's Business Daily
Nov-02-17 04:04PM  The Clear Reason Exelixis, Inc. Rocketed Higher by as Much as 10% Motley Fool +5.32%
12:08PM  Agios (AGIO) Q3 Loss Narrower than Expected, Revenues Up Y/Y Zacks
10:36AM  Exelixis (EXEL) Beats Q3 Earnings on Solid Cabometyx Sales Zacks
10:19AM  Conatus (CNAT) Loss Wider Than Expected in Q3, Sales Miss Zacks
10:15AM  Sucampo (SCMP) Beats on Q3 Earnings & Revenues, Ups '17 View Zacks
10:02AM  Intercept (ICPT) Q3 Loss Narrower Than Expected, Sales Beat Zacks
Nov-01-17 05:59PM  Exelixis tops Street 3Q forecasts Associated Press
05:47PM  Neurocrine, Exelixis, Juno Stocks Rocket After Crushing Views Investor's Business Daily
04:05PM  Exelixis Announces Third Quarter 2017 Financial Results and Provides Corporate Update Business Wire
02:58PM  Acorda (ACOR) Q3 Earnings Lag Estimates, Revenues Up Y/Y Zacks
12:30PM  Exelixis, Inc. to Host Earnings Call ACCESSWIRE
Oct-31-17 07:34AM  If Celgene Buys This Biotech, Investors Should Win Big Time Motley Fool
Oct-30-17 11:46AM  ETFs with exposure to Exelixis, Inc. : October 30, 2017 Capital Cube
08:12AM  Exelixis, Inc. breached its 50 day moving average in a Bullish Manner : EXEL-US : October 30, 2017 Capital Cube
Oct-27-17 01:05PM  What's in the Offing for Exelixis (EXEL) in Q3 Earnings? Zacks
Oct-26-17 04:10PM  Exelixis to Present at the Credit Suisse 26th Annual Healthcare Conference on November 7th Business Wire
Oct-24-17 08:16AM  3 Top Biotech Stocks to Buy Now Motley Fool
Oct-21-17 10:48AM  Better Buy: Exelixis, Inc. vs. Intra-Cellular Therapies Inc. Motley Fool
Oct-20-17 05:28PM  Cancer Treatment Update: Second Gene Therapy Receives Approval Zacks
10:12AM  ETFs with exposure to Exelixis, Inc. : October 20, 2017 Capital Cube
Oct-19-17 08:00AM  Exelixis, Positive News from Celestial Study, Cabometyx Label Review Due February 15, 2018 ACCESSWIRE
Oct-18-17 04:05PM  Exelixis to Release Third Quarter 2017 Financial Results on Wednesday, November 1, 2017 Business Wire
07:50AM  Featured Company News - Exelixis' Cabozantinib Met Primary Endpoint in Phase-3 CELESTIAL Trial for Advanced Hepatocellular Carcinoma ACCESSWIRE
07:32AM  Biotech Stock Roundup: Exelixis Soars on Priority Review, FDA Panel Supports Spark Drug Zacks
Oct-17-17 10:03AM  Company News For Oct 17, 2017 Zacks
09:15AM  FDA Grants Priority Review for Exelixis' RCC Drug Cabomteyx Zacks
08:33AM  Exelixis (EXEL) Looks Good: Stock Adds 17.2% in Session Zacks
08:18AM  Why Exelixis' Rebound Is Just Getting Started Motley Fool
08:10AM  Today's Research Reports on Stocks to Watch: Dynavax and Exelixis ACCESSWIRE
08:05AM  Exelixis, Inc. breached its 50 day moving average in a Bullish Manner : EXEL-US : October 17, 2017 Capital Cube
Oct-16-17 05:04PM  What Happened in the Stock Market Today Motley Fool +17.21%
04:40PM  Exelixis Rockets To 17-Year High On Kidney, Liver Cancer News Investor's Business Daily
04:32PM  Exelixis and Ruby Tuesday rise while Nordstrom and Tesla dip Associated Press
03:49PM  Wall Street High on Monday GuruFocus.com
12:57PM  Why Exelixis, Inc. Rose Higher Today Motley Fool
09:22AM  Exelixis Pops on Phase 3 Data for Liver Cancer Drug -- Biotech Movers TheStreet.com
09:22AM  Exelixis Pops as FDA Gives Kidney Cancer Drug Priority Review -- Biotech Movers TheStreet.com
09:10AM  Exelixis Cancer Treatment Hits Key Milestone 24/7 Wall St.
07:26AM  Exelixis shares surge 19% premarket after FDA grants priority review to kidney cancer drug MarketWatch
07:15AM  Exelixis cancer drug meets key goal in late-stage trial Reuters
07:02AM  Ipsen Announces That Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival in Patients with Advanced Hepatocellular Carcinoma Business Wire
06:59AM  Exelixis Announces U.S. FDA Grants Priority Review for CABOMETYX® (Cabozantinib) as a Treatment for Previously Untreated Advanced Renal Cell Carcinoma Business Wire
06:58AM  Exelixis Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival in Patients with Advanced Hepatocellular Carcinoma Business Wire
Oct-09-17 11:30AM  ETFs with exposure to Exelixis, Inc. : October 9, 2017 Capital Cube
08:04AM  See what the IHS Markit Score report has to say about Exelixis Inc. Markit
Oct-06-17 09:11AM  Exelixis, Inc. :EXEL-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017 Capital Cube
08:15AM  New Research: Key Drivers of Growth for Bed Bath and Beyond, The Finish Line, Exelixis, Garmin, Juno Therapeutics, and Mattel - A Look Behind the Scenes at Consolidated Results, Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Exelixis, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer. The company's products include CABOMETYX for the treatment of patients with advanced renal cell carcinoma, who have received prior anti-angiogenic therapy; and COMETRIQ for the treatment of patients with progressive, metastatic medullary thyroid carcinoma. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors, which has shown clinical anti-tumor activity in approximately 20 forms of cancer and is the subject of a broad clinical development program. It also offers COTELLIC (cobimetinib), a selective inhibitor of MEK, in combination with vemurafenib for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma in the United States; and in combination with vemurafenib in other territories, including the European Union, Switzerland, Canada, Australia, and Brazil. Exelixis, Inc. has collaboration and license agreements with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds and programs. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schwab GiselaPres Prod Dev & Med Aff & CMOSep 28Option Exercise9.9133,334330,340216,339Sep 28 07:45 PM
Hessekiel JeffreyEVP and General CounselSep 28Option Exercise1.9025,00047,500292,946Sep 28 07:47 PM
Hessekiel JeffreyEVP and General CounselSep 28Sale24.3225,000608,000267,946Sep 28 07:47 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOSep 28Sale23.7433,334791,349183,005Sep 28 07:45 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOSep 27Option Exercise9.9133,333330,330216,338Sep 28 07:45 PM
Hessekiel JeffreyEVP and General CounselSep 27Option Exercise1.902,3024,374270,248Sep 28 07:47 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOSep 27Sale23.9433,333797,992183,005Sep 28 07:45 PM
Hessekiel JeffreyEVP and General CounselSep 27Sale23.902,30255,018267,946Sep 28 07:47 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOSep 26Option Exercise9.9133,333330,330216,338Sep 28 07:45 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOSep 26Sale23.6833,333789,325183,005Sep 28 07:45 PM
PAPADOPOULOS STELIOSDirectorSep 22Sale25.4010,000254,0000Sep 22 07:07 PM
PAPADOPOULOS STELIOSDirectorSep 19Sale27.63127,7903,530,8381,034,314Sep 20 06:48 PM
PAPADOPOULOS STELIOSDirectorSep 18Sale27.7672,2102,004,5501,162,104Sep 20 06:48 PM
MORRISSEY MICHAELPresident and CEOSep 14Option Exercise1.70100,000170,000160,000Sep 14 07:14 PM
MORRISSEY MICHAELPresident and CEOSep 14Sale27.08100,0002,708,00060,000Sep 14 07:14 PM
Haley Patrick J.Sr. Vice President, CommercialSep 14Sale27.2160,6401,650,01441,553Sep 15 06:43 PM
MORRISSEY MICHAELPresident and CEOSep 13Option Exercise1.70100,000170,000160,000Sep 14 07:14 PM
MORRISSEY MICHAELPresident and CEOSep 13Sale27.04100,0002,704,00060,000Sep 14 07:14 PM
WILLSEY LANCEDirectorSep 13Sale26.9750,0001,348,500468,273Sep 14 07:18 PM
Senner Christopher J.EVP and CFOSep 12Option Exercise3.66100,000366,000202,759Sep 14 07:17 PM
MORRISSEY MICHAELPresident and CEOSep 12Option Exercise1.70100,000170,000160,000Sep 14 07:14 PM
MORRISSEY MICHAELPresident and CEOSep 12Sale26.59100,0002,659,00060,000Sep 14 07:14 PM
WILLSEY LANCEDirectorSep 12Sale26.7950,0001,339,500518,273Sep 14 07:18 PM
Senner Christopher J.EVP and CFOSep 12Sale26.79100,0002,679,000102,759Sep 14 07:17 PM
Haley Patrick J.Sr. Vice President, CommercialMay 30Sale18.465,00092,300102,193Jun 01 07:09 PM
FELDBAUM CARL BDirectorMay 15Option Exercise8.7519,000166,19067,721May 16 09:13 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOMay 15Option Exercise5.0412,50163,005183,005May 16 09:12 PM
FELDBAUM CARL BDirectorMay 15Sale21.5832,988711,83134,733May 16 09:13 PM
MORRISSEY MICHAELPresident and CEOMay 10Option Exercise1.86100,000185,910160,000May 10 08:07 PM
MORRISSEY MICHAELPresident and CEOMay 10Sale22.07100,0002,207,00060,000May 10 08:07 PM
MORRISSEY MICHAELPresident and CEOMay 09Option Exercise1.90100,000190,000111,214May 10 08:07 PM
MORRISSEY MICHAELPresident and CEOMay 09Sale21.69100,0002,168,70660,000May 10 08:07 PM
MORRISSEY MICHAELPresident and CEOMay 08Option Exercise1.9011,30021,47071,300May 10 08:07 PM
MORRISSEY MICHAELPresident and CEOMay 08Sale21.8111,300246,45360,000May 10 08:07 PM
MORRISSEY MICHAELPresident and CEOMay 05Option Exercise1.90100,000190,000149,555May 05 06:53 PM
MORRISSEY MICHAELPresident and CEOMay 05Sale21.85100,0002,184,70260,000May 05 06:53 PM
MORRISSEY MICHAELPresident and CEOMay 04Option Exercise1.9059,149112,383119,149May 05 06:53 PM
MORRISSEY MICHAELPresident and CEOMay 04Sale22.1759,1491,311,33360,000May 05 06:53 PM
MORRISSEY MICHAELPresident and CEOMay 03Option Exercise1.90100,000190,000129,427May 05 06:53 PM
MORRISSEY MICHAELPresident and CEOMay 03Sale22.67100,0002,266,80360,000May 05 06:53 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOMay 01Option Exercise9.9189,910891,008260,414May 03 08:02 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOMay 01Sale23.0189,9102,068,519170,504May 03 08:02 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOApr 17Option Exercise9.9110,09099,992168,143Apr 18 07:57 PM
MARCHESI VINCENT TDirectorApr 03Option Exercise10.5310,000105,300130,070Apr 04 08:00 PM
MARCHESI VINCENT TDirectorApr 03Sale21.3010,000213,000120,070Apr 04 08:00 PM
WYSZOMIERSKI JACK LDirectorMar 31Option Exercise10.5310,000105,30078,110Mar 31 06:35 PM
WYSZOMIERSKI JACK LDirectorMar 31Sale21.575,150111,08672,960Mar 31 06:35 PM
COHEN CHARLESDirectorMar 27Option Exercise10.5310,000105,300248,180Mar 28 08:15 PM
Hessekiel JeffreyEVP and General CounselMar 27Sale21.026,884144,702267,946Mar 28 08:15 PM
Hessekiel JeffreyEVP and General CounselMar 22Option Exercise1.7055,00093,500301,617Mar 24 07:41 PM
Hessekiel JeffreyEVP and General CounselMar 22Sale20.5423,787488,585277,830Mar 24 07:41 PM
PAPADOPOULOS STELIOSDirectorMar 20Option Exercise10.5310,000105,3001,238,471Mar 21 07:28 PM
FELDBAUM CARL BDirectorMar 20Option Exercise10.5310,000105,30058,721Mar 21 07:29 PM
FELDBAUM CARL BDirectorMar 20Sale21.7710,000217,70048,721Mar 21 07:29 PM
PAPADOPOULOS STELIOSDirectorMar 20Sale21.6610,000216,6001,228,471Mar 21 07:28 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOMar 15Option Exercise6.2050,007310,179208,060Mar 17 07:51 PM
WILLSEY LANCEDirectorMar 15Option Exercise10.5310,000105,300578,273Mar 17 07:52 PM
WILLSEY LANCEDirectorMar 15Sale22.8610,000228,600568,273Mar 17 07:52 PM
Schwab GiselaPres Prod Dev & Med Aff & CMOMar 15Sale22.5350,0071,126,658158,053Mar 17 07:51 PM
COHEN CHARLESDirectorMar 13Sale21.8210,000218,200238,180Mar 14 08:12 PM
MARCHESI VINCENT TDirectorMar 10Option Exercise3.1340,000125,200160,070Mar 10 07:37 PM
MARCHESI VINCENT TDirectorMar 10Sale21.9840,000879,200120,070Mar 10 07:37 PM
MORRISSEY MICHAELPresident and CEOMar 06Option Exercise9.91100,000991,000160,000Mar 07 07:56 PM
MORRISSEY MICHAELPresident and CEOMar 06Sale22.61100,0002,261,00060,000Mar 07 07:56 PM
Hessekiel JeffreyEVP and General CounselMar 03Option Exercise7.27100,000727,000346,617Mar 07 08:00 PM
MORRISSEY MICHAELPresident and CEOMar 03Option Exercise9.91100,000991,000160,000Mar 07 07:56 PM
Senner Christopher J.EVP and CFOMar 03Sale22.8011,000250,800100,398Mar 03 08:20 PM
Haley Patrick J.Sr. Vice President, CommercialMar 03Sale23.042,50057,600107,193Mar 07 07:45 PM
MORRISSEY MICHAELPresident and CEOMar 03Sale22.83100,0002,283,00060,000Mar 07 07:56 PM
Hessekiel JeffreyEVP and General CounselMar 03Sale23.04100,0002,303,678246,617Mar 07 08:00 PM
POSTE GEORGEDirectorMar 02Option Exercise4.5167,400303,660144,955Mar 03 08:17 PM
POSTE GEORGEDirectorMar 02Sale22.5867,4001,521,89277,555Mar 03 08:17 PM
POSTE GEORGEDirectorMar 01Option Exercise10.538,85093,19186,405Mar 03 08:17 PM
Lamb PeterEVP, Scientific Strategy & CSOMar 01Option Exercise7.3645,000331,350118,600Mar 03 08:18 PM
Lamb PeterEVP, Scientific Strategy & CSOMar 01Sale22.1945,000998,55073,600Mar 03 08:18 PM
POSTE GEORGEDirectorMar 01Sale22.188,850196,29377,555Mar 03 08:17 PM
Lamb PeterEVP, Scientific Strategy & CSOFeb 01Option Exercise6.9270,000484,300143,600Feb 03 07:55 PM
Lamb PeterEVP, Scientific Strategy & CSOFeb 01Sale18.6570,0001,305,50073,600Feb 03 07:55 PM
Lamb PeterEVP, Scientific Strategy & CSOJan 03Option Exercise5.7470,000401,800143,600Jan 05 08:25 PM
Lamb PeterEVP, Scientific Strategy & CSOJan 03Sale14.6570,0001,025,63673,600Jan 05 08:25 PM
FELDBAUM CARL BDirectorDec 16Option Exercise10.4125,000260,25073,721Dec 16 07:29 PM
FELDBAUM CARL BDirectorDec 16Sale17.0325,000425,75048,721Dec 16 07:29 PM